Immune cell-derived type I IFNs drive anti-tumor immunity against many cancers (10), and STING-deficient animals show increased tumorigenesis and intratumoral administration of small molecule STING agonists eliminating tumors in vivo (11, 12). Here, STING1 is linked to cancer.